Skip to main content
. Author manuscript; available in PMC: 2009 Nov 15.
Published in final edited form as: Bioorg Med Chem Lett. 2008 Sep 12;18(22):5941–5944. doi: 10.1016/j.bmcl.2008.09.043

Figure 1.

Figure 1

(A) Mean fluorescence intensity of C-terminal FKBP mutants in the absence of Shield-1. (B) NIH3T3 cells stably expressing YFP-FKBP fusions were treated with varying concentrations of Shield-1 (1 nM to 10 μM) for 24h and analyzed by flow cytometry. Data for panels A and B are presented as a percentage of the maximum fluorescence intensity observed for the individual mutant for an experiment performed in triplicate (± s.d).

HHS Vulnerability Disclosure